576 related articles for article (PubMed ID: 22301476)
21. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
[TBL] [Abstract][Full Text] [Related]
22. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
[TBL] [Abstract][Full Text] [Related]
23. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
[TBL] [Abstract][Full Text] [Related]
24. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
[TBL] [Abstract][Full Text] [Related]
25. Phase III, randomized controlled trial to evaluate lot consistency of a trivalent subunit egg-based influenza vaccine in adults.
Rivera L; Mazara S; Vargas M; Fragapane E; Casula D; Groth N
Vaccine; 2012 Jul; 30(35):5285-92. PubMed ID: 22659448
[TBL] [Abstract][Full Text] [Related]
26. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
Nolan T; Bravo L; Ceballos A; Mitha E; Gray G; Quiambao B; Patel SS; Bizjajeva S; Bock H; Nazaire-Bermal N; Forleo-Neto E; Cioppa GD; Narasimhan V
Vaccine; 2014 Oct; 32(46):6146-56. PubMed ID: 25223266
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.
Frey S; Vesikari T; Szymczakiewicz-Multanowska A; Lattanzi M; Izu A; Groth N; Holmes S
Clin Infect Dis; 2010 Nov; 51(9):997-1004. PubMed ID: 20868284
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM
J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042
[TBL] [Abstract][Full Text] [Related]
30. Comparison of immunogenicity and reactogenicity of split versus subunit influenza vaccine in Korean children aged 6-35 months.
Kim YK; Eun BW; Kim NH; Kang EK; Lee BS; Kim DH; Lim JS
Scand J Infect Dis; 2013 Jun; 45(6):460-8. PubMed ID: 23294036
[TBL] [Abstract][Full Text] [Related]
31. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
Mallory RM; Yi T; Ambrose CS
Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia.
Souza AR; Braga JA; de Paiva TM; Loggetto SR; Azevedo RS; Weckx LY
Vaccine; 2010 Jan; 28(4):1117-20. PubMed ID: 20116631
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety of three 2010-2011 seasonal trivalent influenza vaccines in Chinese toddlers, children and older adults: a double-blind and randomized trial.
Luo FJ; Yang LQ; Ai X; Bai YH; Wu J; Li SM; Zhang Z; Lu M; Li L; Wang ZY; Shi NM
Hum Vaccin Immunother; 2013 Aug; 9(8):1725-34. PubMed ID: 23896581
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
Vinnemeier CD; Fischer-Herr J; Meyer S; Liebig K; Theeß W; Burchard GD; Cramer JP
Hum Vaccin Immunother; 2014; 10(2):441-8. PubMed ID: 24240428
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
Domachowske JB; Pankow-Culot H; Bautista M; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
J Infect Dis; 2013 Jun; 207(12):1878-87. PubMed ID: 23470848
[TBL] [Abstract][Full Text] [Related]
38. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety.
Madhi SA; Maskew M; Koen A; Kuwanda L; Besselaar TG; Naidoo D; Cohen C; Valette M; Cutland CL; Sanne I
Clin Infect Dis; 2011 Jan; 52(1):128-37. PubMed ID: 21148531
[TBL] [Abstract][Full Text] [Related]
39. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial.
Groth N; Montomoli E; Gentile C; Manini I; Bugarini R; Podda A
Vaccine; 2009 Jan; 27(5):786-91. PubMed ID: 19027046
[TBL] [Abstract][Full Text] [Related]
40. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
van de Witte S; Nauta J; Montomoli E; Weckx J
Vaccine; 2018 Sep; 36(40):6030-6038. PubMed ID: 29709447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
